Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange with Albutein 5% in Patients with Amyotrophic Lateral Sclerosis
Principal Investigator (?)
This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in subjects with amyotrophic lateral sclerosis (ALS).
Grifols Inc. (US)
Available at the following location(s)